Adjuvant checkpoint inhibitor therapy is the standard of care for resectable melanoma. Although many patients derive lasting benefit from the treatment, a substantial number experience disease recurrence.
Regulatory
SkylineDx Announces Grant of European Patent and Advances in Melanoma Diagnosis and Treatment
ROTTERDAM, Netherlands and SAN DIEGO, Jan. 9, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European Patent Office (EPO) has granted European Patent No. 3827101, marking a groundbreaking advancement in the field of cancer diagnostics and personalized treatment.
Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma
Bristol Myers Squibb’s (BMS) Opdualag (nivolumab-relatlimab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line treatment of advanced melanoma in patients aged 12 years and older.
NICE Approves Nivolumab and Relatlimab Combination for Advanced Melanoma Treatment
The National Institute for Health and Care Excellence (NICE) has made a significant stride in the management of advanced melanoma by approving the drug combination of nivolumab and relatlimab as a first-line treatment.